SiDMAP Chief Scientist to Collaborate on Cancer Research Grant with Johns Hopkins School of Medicine

LOS ANGELES--(BUSINESS WIRE)-- SiDMAP, LLC (www.sidmap.com), a privately held life-science company that provides metabolomics research services to the pharmaceutical and biotechnology industries and the academic biomedical research community worldwide, announced today that its Chief Scientist, Laszlo Boros, M.D., has been designated as Co-Principal Investigator on a new cancer research grant awarded to the Johns Hopkins School of Medicine.

The new grant, funded by the National Institutes of Health / National Cancer Institute, provides support for metabolic profiling research in lung cancer. Shyam Biswal, Ph.D., Associate Professor at Johns Hopkins University, School of Medicine, in Baltimore, is Principal Investigator on the grant.

Entitled “Regulation of Tumorigenesis and Therapeutic Resistance by Nrf2 in Lung Cancer,” the grant will test the hypothesis that a gain in function of the gene transcription factor Nrf2 (Nuclear factor erythroid-2 related factor) promotes tumorigenesis in the presence of an oncogenic (cancer-causing) signal.

"SiDMAP opens new avenues for understanding and treating cancer by revealing the functional impact of known gene mutations on a complex hierarchy of metabolic reactions,” said Dr. Boros. He added, “SiDMAP is always glad to collaborate with top university investigators, such as our colleagues at Johns Hopkins, to accelerate research in the cancer field.”

Dr. Boros, a SiDMAP co-founder and Associate Professor at the UCLA School of Medicine, is a leading expert on the basic science and translational research applications of metabolomics, an evolving field of research focusing on metabolic changes associated with disease processes and response to drug treatment. Metabolomics studies are used by drug researchers to elucidate a drug’s mechanism of action (MOA) by identifying and measuring myriad metabolic changes that occur in cells and organs following drug administration. Metabolomics studies can also reveal early metabolic changes associated with increased potential for drug toxicity, and can be used to screen for cellular, animal model or patient phenotypes that respond more or less favorably to a particular drug. Metabolomics testing is also being used increasingly as a very precise tool for identifying novel drug targets, such as key enzymes that play critical roles in the function of metabolic pathways essential for the growth of cancer cells.

Dr. Boros and his research team at SiDMAP will collaborate with Dr. Biswal and his team at Johns Hopkins to determine whether a gain in Nrf2 function increases glucose metabolism via the pentose phosphate pathway and tricarboxlyic acid pathway—metabolic steps essential to tumorigenesis. The grant further seeks to determine if blocking Nrf2-dependent phosphate pathway enzymes inhibits growth of NSCLC cells and limits chemoresistance.

Use of SiDMAP’s proprietary stable-isotope dynamic metabolic profiling technology in the NIH/NCI-funded study at Johns Hopkins will help in understanding the regulation of lung tumorigenesis by a novel pathway and in developing a strategy for targeting this pathway to circumvent therapeutic resistance.



CONTACT:

SiDMAP, LLC
Kate Hawkes
Manager, Business Development & Administration
Phone: 310-478-1424, ext. 308
[email protected]

KEYWORDS:   United States  North America  California  Maryland

INDUSTRY KEYWORDS:   Education  University  Health  Biotechnology  Oncology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.